Clinical Trials
Oncotelic Therapeutics Doses First Patient in Phase 1b Trial of Sapu003 for Advanced Solid Tumors
Oncotelic Therapeutics and Sapu Nano announced the first patient dosed in a Phase 1b trial of Sapu003, an IV formulation of everolimus, aiming to improve delivery and reduce toxicity for advanced mTOR-sensitive solid tumors.
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
The rising prevalence of obesity and type 2 diabetes is driving significant interest in next-generation GLP-1 therapies, with companies like SureNano Science Ltd. developing novel triple agonists that could improve efficacy and tolerability in a rapidly expanding market.
Kairos Pharma CEO to Present at LD Micro Invitational, Highlighting Clinical Progress
Kairos Pharma CEO Dr. John Yu will present at the LD Micro Invitational, providing updates on the company's clinical trials for ENV-105, a promising oncology candidate targeting drug resistance in cancer.
NHS Rolls Out One-Minute Immunotherapy Injection for Cancer Patients
The NHS in England is offering thousands of cancer patients a one-minute injection of pembrolizumab instead of a lengthy infusion, significantly reducing administration time.
OS Therapies Gains Regulatory Clarity for OST-HER2 in Osteosarcoma, Stonegate Capital Reports
Stonegate Capital Partners updates coverage on OS Therapies, highlighting EMA rolling review and TGA endpoint alignment that shift OST-HER2 toward a global approval pathway, with key survival data catalysts in 2026.
Tonix Pharmaceuticals Reports Q1 2026 Results, Highlights TONMYA Commercial Growth and Pipeline Progress
Tonix Pharmaceuticals reported Q1 2026 financial results, showing early commercial success for its fibromyalgia drug TONMYA and advancing pipeline candidates including a Lyme disease prevention therapy.
Aclarion Adds First Private Practice Site in Los Angeles to CLARITY Trial
Aclarion announced the addition of Lanman Spinal Neurosurgery in Beverly Hills to its CLARITY trial, expanding enrollment beyond academic centers and highlighting growing interest in Nociscan for precise chronic low back pain diagnosis.
Study Suggests Earlier Immunotherapy Could Improve Survival in Late-Stage Solid Tumors
A systematic review in JAMA Network Open indicates that earlier administration of immune checkpoint inhibitor therapies may improve survival outcomes for patients with late-stage solid tumors, though further validation is needed.
SureNano Science Launches IND-Enabling Program for Obesity and Diabetes Drug GEP-44, Targeting a $200 Billion Market
SureNano Science has initiated an FDA-aligned GLP toxicology and pharmacology program for its lead candidate GEP-44, a multi-receptor peptide for obesity and type 2 diabetes, positioning the company to enter the rapidly growing GLP-1 market projected to reach $200 billion by 2030.
HeartBeam Launches Pilot Study for On-Demand 12-Lead ECG Patch Aimed at Ischemia Detection
HeartBeam Inc. has initiated a pilot study for its investigational on-demand 12-lead ECG patch in coronary artery disease patients, potentially expanding ambulatory cardiac monitoring into ischemia detection within a $2 billion market.
Pipeline Maturity Reshapes Biotech Valuations as Clinical Progress Gains Weight
The biotechnology industry's valuation model is shifting from a revenue-centric approach to one that prioritizes clinical-stage progression and probability of success, with companies like Oncotelic Therapeutics exemplifying this trend.
Annovis Bio CEO to Present Multi-Protein Approach to Alzheimer's at Fierce Biotech Week 2026
Annovis Bio CEO will present the company's multi-protein targeting strategy for Alzheimer's disease at Fierce Biotech Week 2026, highlighting buntanetap's Phase 3 trial.
Oragenics Advances Phase IIa Trial for Concussion Treatment, Targeting Data Readout by 2026
Oragenics Inc. is actively enrolling patients at a second site in its Phase IIa trial for ONP-002, a potential first-in-class treatment for concussion, with a data readout expected by end of 2026.
Aclarion Expands Nociscan Use at Weill Cornell Medicine in New Trial on Disc Degeneration
Aclarion's second commercial agreement with Weill Cornell Medicine will deploy its Nociscan platform in a randomized controlled trial led by Dr. Roger Härtl, aiming to improve understanding and treatment of degenerative disc disease.
Vitamin D Supplement Found to Boost Chemotherapy Efficacy in Breast Cancer Patients
A Brazilian clinical trial reveals that daily vitamin D supplementation improves outcomes for women undergoing standard chemotherapy for breast cancer, highlighting a low-cost intervention with global implications.
CNS Pharmaceuticals Raises $22.5 Million to Advance Pipeline and Corporate Strategy
CNS Pharmaceuticals announced a $22.5 million private placement with institutional investors to fund asset acquisition and working capital, signaling a strategic push to expand its pipeline.
BioVersys Shareholders Approve All Board Proposals, Including New Board Member and Compensation Packages
BioVersys AG announced that shareholders approved all board proposals at its annual general meeting, including the re-election of directors and election of a new board member, as the company advances its lead antibiotic candidate into Phase 3 trials.
Telomir Pharmaceuticals Gains FDA Clearance for Telomir-Zn Phase 1/2 Trial in Triple-Negative Breast Cancer
Telomir Pharmaceuticals announced FDA IND clearance for Telomir-Zn to treat advanced triple-negative breast cancer, allowing a Phase 1/2 trial to proceed and marking a key step toward clinical development.
Aclarion Reports 196% Surge in Nociscan Scans, Advances Reimbursement and Clinical Trials
Aclarion's Q1 2026 results show a 196% year-over-year increase in Nociscan scan volumes, driven by clinical adoption and payer coverage, with a strong cash position and upcoming CLARITY trial data expected in late 2026.
Tonix Pharmaceuticals Advances Lyme Disease Prevention with Phase 1 Data and Plans for Phase 2 Study
Tonix Pharmaceuticals reported Phase 1 data for its Lyme disease prevention candidate TNX-4800 and announced plans for an adaptive Phase 2 field study, highlighting the unmet need for prophylactic options in the U.S.
GeoVax Advances Gedeptin Toward Phase 2 Initiation and Strategic Partnership Opportunities
GeoVax Labs outlines near-term milestones for its oncology candidate Gedeptin, including a planned Phase 2 trial in head and neck cancer, as it seeks combination therapy partnerships.
ARMR Sciences Advances Fentanyl Vaccine Toward Human Trials with Private Placement
ARMR Sciences Inc. completed a private placement financing led by Joseph Gunnar & Co. to advance its preventive fentanyl vaccine toward human trials, aiming to address the synthetic drug crisis.
Helus Pharma Partners with TARA Mind to Boost Veteran Recruitment in Phase 3 Depression Trial
Helus Pharma collaborates with TARA Mind and VETS to recruit veterans for its Phase 3 trial of HLP003 for major depressive disorder, aligning with a recent executive order on mental health.
New Molecule Shows Promise for Glioblastoma Treatment, Clinical Trial Underway
Researchers at Brown University Health have identified a molecule that may alter glioblastoma treatment, with a clinical trial planning direct surgical delivery to the tumor.
SureNano Science Advances GLP-1 Drug Candidate Toward Clinical Trials, Expands Investor Outreach
SureNano Science Ltd. is moving its lead obesity and diabetes drug GEP-44 into FDA IND-enabling studies with LabCorp while broadening investor communications through a partnership with Investor Brand Network.
Cingulate Advances ADHD Treatment Toward 2026 FDA Decision with Key Milestones
Cingulate Inc. progresses toward potential 2026 commercial launch of its ADHD treatment CTx-1301 following FDA acceptance of its New Drug Application and positive pediatric trial results, addressing a large market with unmet needs.
NRx Pharmaceuticals Receives Positive FDA Review for Ketamine ANDA, Targets 2026 Approval
NRx Pharmaceuticals has received a positive FDA review letter for its ketamine ANDA and reported a supportive meeting with FDA leadership, advancing its preservative-free ketamine product toward potential approval in summer 2026 for treating severe mental illness.
Tonix Pharmaceuticals Publishes Pharmacokinetic Study Supporting TONMYA's Mechanism for Fibromyalgia Treatment
Tonix Pharmaceuticals' peer-reviewed study demonstrates TONMYA's superior pharmacokinetic profile compared to oral cyclobenzaprine, supporting its use as the first new fibromyalgia treatment in over 15 years.
Analytical Validation Strengthens Soligenix Outlook as Pipeline Advances
A recent Zacks Small-Cap Research report highlights Soligenix's clinical progress and upcoming milestones, particularly in its phase 3 FLASH2 trial for cutaneous T-cell lymphoma treatment, reinforcing the company's strategic credibility and valuation potential.
GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial Amid Global Supply Concerns
GeoVax Labs is preparing to initiate a pivotal Phase 3 trial for its GEO-MVA vaccine in the second half of 2026, addressing critical global supply constraints for orthopoxvirus vaccines while reporting a reduced net loss of $21.5 million for 2025.